

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 December 2002 (12.12.2002)

PCT

(10) International Publication Number
WO 02/098286 A2

- (51) International Patent Classification⁷: **A61B**
- (21) International Application Number: PCT/US02/18249
- (22) International Filing Date: 6 June 2002 (06.06.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/875,388 6 June 2001 (06.06.2001) US
- (71) Applicants: **THE TRUSTEES OF COLUMBIA UNIVERSITY IN CITY OF NEW YORK** [US/US]; West 116th Street and Broadway, New York, NY 10027 (US). **THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK** [US/US]; Office of Technology Licensing and Industry Relations, N5002 Melville Library, Stony Brook, NY 11794-3369 (US).
- (72) Inventors: **ROSEN, Michael, R.**; 25 East 86th Street, Apt. 14C, New York, NY 10028 (US). **ROBINSON, Richard, B.**; 67 Roosevelt Street, Cresskill, NJ 07626 (US). **COHEN, Ira, S.**; 23 Hawks Nest Road, Stony Brook, NY 11790 (US). **YU, Han-Gang**; 15 Hollow Road, Stony Brook, NY 11790 (US).
- (74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/098286 A2

(54) Title: IMPLANTATION OF BIOLOGICAL PACEMAKER THAT IS MOLECULARLY DETERMINED

(57) Abstract: This invention provides for a method of inducing a current in the heart in a subject which comprises contacting a cell of the heart of a subject with a compound in a sufficient amount to induce a current in the cell of the heart of a subject. This invention also provides a method of treating a cardiac condition in a subject which comprises contacting a cell of the heart of the subject with a compound in an amount sufficient to increase the current expression of the cell, thereby treating the cardiac condition in the subject.

BEST AVAILABLE COPY

IMPLANTATION OF BIOLOGICAL PACEMAKER THAT IS MOLECULARLY DETERMINED

This application claims priority of U.S. Serial No. 09/875,388, filed
5 June 6, 2001, the contents of which are hereby incorporated by
reference into this application.

The invention disclosed herein was made with Government support under
NIH Grant Nos. HL-28958, HL-20558, NS-36658 from the National
Institutes of Health. Accordingly, the U.S. Government has certain
10 rights in this invention.

BACKGROUND OF THE INVENTION

The present invention relates to a biological heart pacemaker, and
more importantly to an implantation in the heart of a biological
pacemaker that is molecularly determined.

15 Throughout this application, various publications are referenced to
by numbers. Full citations for these publications may be found at
the end of the specification immediately preceding the claims. The
disclosures of these publications in their entireties are hereby
incorporated by reference into this application in order to more
20 fully describe the state of the art to those skilled therein as of
the date of the invention described and claimed herein.

The pacemaker current, I_f , is present in both automatic (1) and non-
automatic (2-6) regions of the heart. Further, the threshold voltage
of activation varies widely among cardiac regions, being least
25 negative in the sinus node (e.g. in rabbit sinus node it is -40 mV
(7)) and most negative in the ventricle (-108 mV or more negative,
depending on species (5,8,9). Interestingly, the current activates
at less negative voltages in the newborn ventricle (approximately -70

mV in rat (8,10)) and the diseased adult ventricle (approximately -70 mV threshold in aged hypertensive rat(11), -55 mV in failing human ventricle (12)). The molecular and cellular bases for the regional variability of activation voltages in the normal adult heart and the
5 regulation of ventricular activation voltage by development and disease remain to be determined, but such understanding is critical to any future therapeutic application of the expressed current in myocardium.

SUMMARY OF THE INVENTION

- This invention provides a method for the regulation of pacemaker function of cardiac muscle cells and/or specialized conducting fibers in the heart with HCN molecules (HCN 1, 2, or 4 isoforms of the pacemaker current I_f) and/or MiRP1 beta subunit, to produce a functioning site of impulse initiation that serves as the initiator of a heartbeat in settings where sinus node function is abnormal and or the sinus beat cannot activate the atria and or the ventricles normally.
- 10 This invention provides a method of treating a cardiac condition in a subject which comprises contacting a cell of the heart of the subject with a compound in an amount sufficient to increase the current expression of the cell, thereby treating the cardiac condition in the subject.
- 15 This invention also provides a method of inducing a current in the heart in a subject which comprises contacting a cell of the heart of a subject with a compound in a sufficient amount to induce a current in the cell of the heart of a subject, thereby inducing a current in the cell of the heart of the subject.
- 20 This invention further provides a method of increasing the heart rate in a subject which comprises contacting a cell of the heart of a subject with a compound in an amount sufficient to decrease the time constant of activation and deactivation of the cell of the heart, thereby increasing the heart rate in the subject.
- 25 This invention further provides a method of inducing a current in a cell which comprises contacting a cell with a compound in a

-4-

sufficient amount to induce a current in the cell, thereby inducing a current in the cell.

This invention further provides a method of causing a contraction of a cell which comprises contacting the cell with a compound in an amount sufficient to induce a current required to cause a contraction of the cell, thereby causing a contraction of the cell.

This invention further provides a method of shortening the time required to activate and deactivate a cell which comprises contacting a cell with a compound in a sufficient amount to decrease the time constant of activation and deactivation of the cell, thereby shortening the time required to activate and deactivate the cell.

This invention further provides a method of changing the membrane potential of a cell which comprises contacting a cell with a compound in a sufficient amount to change the membrane potential of the cell, thereby changing the membrane potential of the cell.

This invention provides a method for the regulation of cardiac cells or specialized conducting fibers in the heart with HCN molecules, HCN 1, 2, or 4 isoforms of the pacemaker current, I_f , and or MiRP1 beta subunit, to produce a functioning site of impulse initiation that serves as the initiator of a heartbeat in settings where sinus node function is abnormal and or the sinus beat cannot activate the atria and or the ventricles.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1A-C: current traces in neonatal ventricular culture of native I_f and expressed HCN2 or HCN4. **A:** records from a control (non-transfected) myocyte. **B:** records from a myocyte co-transfected with pCI-mHCN2 and pEGFP-C1 using lipofectin. **C:** records from a myocyte co-transfected with pCI-mHCN4 and pEGFP-C1 using lipofectin. In all panels, the test voltage varied from -55 to -125 in 10 mV increments. Note, selected traces are omitted from panel (A) for clarity.

Figure 2A-B: activation-voltage relation and kinetics of expressed HCN2 and HCN4 in neonatal ventricle. **A:** I-V curves converted to activation relation using a Boltzmann relation. Activation relation for native current (dashed line) is taken from (28). **B:** time constant of current activation for native I_f and for expressed I_{HCN2} and I_{HCN4} .

Figure 3A-D: current traces from adult ventricular myocytes. **A:** records from an acutely isolated myocyte. **B:** records from an adult myocyte maintained in culture for 48 hours. **C:** records from an adult myocyte infected with AdHCN2 and then maintained in culture for 48 hours. **D:** illustrates voltage protocol. Note the different vertical scale in (C).

Figure 4A-B: activation relation and kinetics of native I_f in adult myocytes. **A:** activation relation for I_f in acutely dissociated and cultured adult ventricular myocytes. **B:** time constant of current activation for native I_f in acutely isolated and cultured adult ventricular myocytes. Neonatal data from Fig. 2 is superimposed as dashed line for comparison.

Figure 5A-B: activation relation and kinetics of I_{HCN2} expressed with

-6-

AdHCN2 in neonatal and adult ventricle. **A:** activation relations for neonatal and adult ventricle cultures as measured by tail currents. **B:** time constant of activation (squares) and deactivation (circles) for neonatal and adult myocytes. **L**

5 to the equation.

Figure 6: regression relation for $V_{1/2}$ of Boltzmann relation as a function of expressed HCN2 current density in neonatal and adult myocytes. Here cultures were infected with AdHCN2. Lines are calculated linear regressions. The vertical and horizontal error bars
10 represent S.E.M. of $V_{1/2}$ and I_{HCN2} , respectively. Inset shows expanded time scale for current densities < 60 pA/pF.

Figure 7: effect of intracellular cAMP on activation relation of expressed HCN2 current in neonate and adult myocytes. Earlier data with control pipette solution (Fig. 5A) are shown as dashed (neonate)
15 and dotted (adult) lines.

Figure 8A-C: show the effect of HCN2 overexpression on spontaneous activity of neonatal ventricle culture. Monolayer culture was infected with AdHCN2 or AdGFP and spontaneous action potentials subsequently recorded with whole-cell patch electrodes. **A:**
20 spontaneous action potentials from a control monolayer culture. **B:** spontaneous action potentials from an AdHCN2 infected monolayer culture. **C:** summary data comparing control, AdHCN2 infected and AdGFP infected cultures with respect to spontaneous rate, slope of phase 4 depolarization and maximum diastolic potential (MDP). Asterisk
25 indicates significant difference relative to control culture; n values for control were 16-17, for AdHCN2 infected were 12-16 and for AdGFP infected were 6.

-7-

Figure 9A-B: effect of HCN2 overexpression in adult ventricular myocytes. **A:** representative anode break excitation tracings from a control myocyte (left, including stimulus time course) and an AdHCN2 infected myocyte (right). Resting potential in the two examples is -66 and -60 mV, respectively. Only selected traces are shown for clarity. **B:** graph of relation between maximal negative potential achieved during anodal stimulation as a function of I_f or I_{HCN2} current density (measured at the end of a 2-sec step to -125 mV). Inset shows current density range of 0-1.2 pA/pF on an expanded time base, with calculated linear regression as solid line.

Figure 10A-G: functional expression of HCN1 and HCN2 channels with and without minK and MiRP1 in *Xenopus* oocytes. The holding potential is -35mV, and the voltage increment is always 10mV. **A:** 5ng HCN1 cRNA injection and test pulses 3-seconds long from -65mV to a maximum voltage of -115mV. **B:** 5ng HCN1 plus 0.2ng minK injection with test pulses 3-seconds long from a minimum voltage of -55mV to a maximum voltage of -115mV. **C:** 5ng HCN1 plus 0.2ng MiRP1 injection with test pulses 3-seconds long from -55mV to -115mV. **D:** 5ng HCN2 cRNA injection with test pulses 8-seconds long from -55mV to -95mV. **E:** 5ng HCN2 plus 0.2ng minK injection with test pulses 8-seconds long from -65mV to -105mV. **F:** 5ng HCN2 plus 0.2ng MiRP1 injection with test pulses 8-seconds long from -55mV to -95mV. **G:** the maximum conductance of the tail current obtained by dividing its amplitude by the driving force at that potential.

Figure 11A-F: gating properties of the expressed channels. **A:** activation curves of HCN1 alone and HCN1 coexpressed with MiRP1. The inset shows the representative tail currents used to construct the activation curve. **B:** activation curves of HCN2 alone and HCN2

-8-

coexpressed with MiRP1. C: sample data illustrating activation kinetics of HCN1 alone and HCN1 coexpressed with MiRP1. D: sample data illustrating activation kinetics of HCN2 alone and HCN2 coexpressed with MiRP1. E: plot of activation and deactivation (in box) time constants for HCN1 alone and HCN1+MiRP1. F: same as (E) but for HCN2 and HCN2+MiRP1.

Figure 12A-B: MiRP1 mRNA expression in rabbit as determined by RNase protection assays. A: represents an example of a representative RPA performed on 2 μ g of total RNA isolated from left ventricle, right atrium, SA node and whole brain. B: histogram showing the relative abundance of MiRP1. Data are normalized to the cyclophilin protected fragment; values are the means of three independent mRNA samples and the error bars are SEM.

Figure 13A-C: western blots showing protein expression of HCN1 channel subunits with and without MiRP1 in *Xenopus* oocytes following immunoprecipitation with the HCN1 ion channel subunit. A: proteins in oocyte membranes fractionated and probed with anti-HCN1 antibody. B: oocyte membrane protein probed with anti-HA antibody. C: products of IP reactions by anti-HCN1 antibody from membrane protein from oocytes injected with HCN1, MiRP1 or by both cRNAs probed with anti-HA antibody.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides a method of treating a cardiac condition in a subject which comprises contacting a cell of the heart of the subject with a compound in an amount sufficient to increase the
5 current expression of the cell, thereby treating the cardiac condition in the subject.

This invention provides the above-described method, wherein the current is the pacemaker current.

This invention also provides the above-described method, wherein the
10 subject is a mammal.

This invention provides the immediately preceding method, wherein the mammal is a human.

This invention further provides the above-described method, wherein the cell is a cardiac myocyte.

15 This invention further provides the above-described method, wherein the cardiac condition is a cardiac rhythm disorder.

This invention provides the immediately preceding method, wherein the cardiac rhythm disorder is selected from a group consisting of conductive block, complete atrioventricular block, incomplete
20 atrioventricular block and sinus node dysfunction.

This invention further provides the above-described method, wherein the compound comprises a nucleic acid which encodes MiRP1.

This invention further provides the above-described method, wherein the compound comprises a nucleic acid which encodes an HCN channel.

-10-

This invention provides the immediately preceding method, wherein the HCN channel is HCN1.

This invention also provides the preceding method, wherein the HCN channel is HCN2.

- 5 This invention further provides the preceding method, wherein the HCN channel is HCN4.

This invention further provides the above-described method, wherein the compound comprises nucleic acids which encodes MiRP1 and a HCN channel.

- 10 This invention provides the immediately preceding method, wherein the HCN channel is HCN1.

This invention also provides the preceding method, wherein the HCN channel is HCN2.

- 15 This invention further provides the preceding method, wherein the HCN channel is HCN4.

- This invention further provides the above-described method
the step of contacting is selected from the group consisting of
topical application, systemic administration to the subject,
injection, electroporation, liposome application, viral-mediated
20 contact, contacting the cell with the nucleic acid, and coculturing
the cell with the nucleic acid.

- This invention provides the immediately preceding method, wherein the
administration of contacting is selected from the group comprising
topical administration, adenovirus infection, viral-mediated
25 infection, liposome-mediated transfer, topical application to the

-11-

cells of the subject, microinjection, and catheterization.

This invention further provides a method of inducing a current in the heart in a subject which comprises contacting a cell of the heart of a subject with a compound in a sufficient amount to induce a current
5 in the cell of the heart of a subject, thereby inducing a current in the cell of the heart of the subject.

This invention further provides a method of increasing the heart rate in a subject which comprises contacting a cell of the heart of a subject with a compound in an amount sufficient to decrease the time
10 constant of activation and deactivation of the cell of the heart, thereby increasing the heart rate in the subject.

This invention further provides a method of inducing a current in a cell which comprises contacting a cell with a compound in a sufficient amount to induce a current in the cell, thereby inducing
15 a current in the cell.

This invention further provides a method of causing a contraction of a cell which comprises contacting the cell with a compound in an amount sufficient to induce a current required to cause a contraction of the cell, thereby causing a contraction of the cell.

20 This invention further provides a method of shortening the time required to activate and deactivate a cell which comprises contacting a cell with a compound in a sufficient amount to decrease the time constant of activation and deactivation of the cell, thereby shortening the time required to activate and deactivate the cell.

25 This invention further provides a method of changing the membrane potential of a cell which comprises contacting a cell with a compound

-12-

in a sufficient amount to change the membrane potential of the cell, thereby changing the membrane potential of the cell.

This invention provides a method for the regulation of cardiac cells
5 or specialized conducting fibers in the heart with HCN molecules, HCN
1, 2, or 4 isoforms of the pacemaker current, I_f , and or MiRP1 beta
subunit, to produce a functioning site of impulse initiation that
e serves as the initiator of a heart
function is abnormal and or the sinus beat cannot activate the atria
10 and or the ventricles.

As used herein, the term "cardiac cell of a heart" means a cell
derived from a heart, either isolated or in culture.

As used herein, the term "a cardiac myocyte" means
from muscle or conductive tissue of a heart, either isolated or in
15 culture and capable of initiating a current.

As used herein, the term "beating rate" means (1) the rate of a
contraction or contractions over a given time period by a cell or (2)
the rate of an electrical pulse or electrical pulses over a given
time period by a cell.

20 As used herein, the term "membrane potential of the cell" means the
transmembrane potential across the plasma membrane of a cell.

As used herein, the term "inducing a current" means causing a cell
to produce an electrical current.

As used herein, the term "time required to activate and deactivate
25 a cell" means the time period from activation of a cell the

-13-

deactivation of the cell.

-14-

EXPERIMENTAL DETAILS EXAMPLE 1:*HCN Over-expression in Newborn and Adult Ventricular Myocytes:
Distinct Effects on Gating and Excitability*

The following abbreviations are used herein: HCN - Hyperpolarization-
5 activated Cyclic Nucleotide gated; minK - minimal K channel protein;
MiRP1 - minK-related peptide 1; I_f - Pacemaker current; mV -
millivolts; cAMP - cyclic adenosine monophosphate; Ad - Adenovirus.

Introduction

Four members of the HCN gene family are currently known (13-15).
10 Three of these (HCN1, HCN2 and HCN4) are present in the heart, but
the relative message level of the three isoforms varies with region
and age (16-18). Sinus node and Purkinje fibers, in which I_f
activates at less negative potentials, contain largely HCN1 and HCN4.
Ventricle contains HCN2 and HCN4, with the ratio of mRNA of HCN2
15 relative to HCN4 being greater in the adult than newborn ventricle.
This suggests that HCN2 is an inherently negatively activating
isoform whose relative abundance determines the activation threshold
in different regions of the heart or at different ages. However,
heterologous expression studies do not support this simple
20 explanation. While there is some variability between laboratories,
when HCN2 and HCN4 have been expressed in mammalian cell lines
activation voltages differed by less than 10 mV (18-20). Thus, the
intrinsic characteristics of the specific HCN isoform expressed does
not seem, by itself, to be a sufficient explanation for the diverse
25 voltage dependence of the native I_f , either regionally in the adult
heart or developmentally in the ventricle.

-15-

An alternative hypothesis is that the cellular environment in which a particular isoform is expressed influences its voltage dependence. The cellular environment could include the presence or absence of beta subunits, cytoskeletal elements, kinases, phosphatases or other factors. Because of these potential differences, HCN2 and/or HCN4 voltage dependence might differ when expressed in myocytes rather than in a heterologous expression system. For the same reason, one or both of these isoforms may be sensitive to the maturational state of the myocyte, exhibiting distinct voltage dependence when expressed in newborn as compared to adult ventricular cells. Here, data is presented to address these issues.

Material and Methods

Cell isolation and culture

Adult rats were anesthetized with ketamine-xylazine before cardiectomy, and neonatal rats decapitated, in accordance with the Institutional Animal Care and Use Committee protocols of Columbia University. For preparing cell cultures of newborn ventricles, a standard trypsin dissociation method was employed (21). The cells were preplated to reduce fibroblast proliferation, cultured initially in serum-containing medium (except when being transfected with plasmids as described below) and then switched to a serum free medium (SFM) after 24 hours. Action potential studies were conducted on 4 day old monolayer cultures plated directly onto fibronectin coated 9 x 22 mm glass coverslips. For voltage clamp experiments, 4-6 day old monolayer cultures were resuspended by brief (2-3 min) exposure to 0.25% trypsin, then the cells replated onto fibronectin-coated coverslips and studied within 2-8 hours.

-16-

Freshly isolated adult ventricle myocytes were prepared using the procedure described by Kuznetsov et al. (22). This entailed a Langendorff perfusion of collagenase, followed by trimming away of the atria. The remaining tissue was minced and dissociated in additional collagenase solution. The isolated myocytes were suspended in a serum free medium (ACCTI (23)) then plated on 9 x 22 mm glass coverslips at $0.5-1 \times 10^3$ cells/mm². Two to three hours later, after the myocytes had adhered to the coverslips, the adenoviral infection procedure was begun (see below).

10 Expression of HCN isoforms

cDNAs encoding mouse HCN2 (mHCN2, GenBank AJ225122) or HCN4 (mHCN4, GenBank deposit in progress) were subcloned into the pCI mammalian Expression Vector (Promega, Madison, WI). The resulting plasmids (pCI-mHCN2 or pCI-mHCN4) were used for neonatal rat ventricular myocyte transfection, as indicated. A separate plasmid (pEGFP-C1; Clontech, Palo Alto, CA) expressing the gene of enhanced green fluorescent protein (GFP) as a visual marker for successful DNA transfer was included in all transfection experiments. For transfection, 2 μ g pCI-mHCN and 1 μ g pEGFP-C1 were first incubated in 200 μ l SFM with 10 μ l lipofectin (Gibco Life Technologies, Rockville, MD) at room temperature for 45 minutes. The mixture was then added to a 35-mm petri dish containing $\sim 10^6$ cells suspended in 0.8 ml SFM. After overnight incubation at 37°C in a CO₂ incubator, the medium containing the plasmids and lipofectin was discarded and the dish was refilled with 2 ml fresh SFM. Patch clamp experiments were carried out on resuspended cells exhibiting detectable levels of GFP by fluorescence microscopy 3-5 days after transfection.

-17-

For increased expression efficiency, an adenoviral construct for mHCN2 was prepared. Gene delivery and transfer procedures followed previously published methods (24,25). A DNA fragment (between EcoRI and XbaI restriction sites) that included mHCN2 DNA downstream of the
5 CMV promoter was obtained from plasmid pTR-mHCN2 (26) and subcloned into the shuttle vector pDC516 (AdMax™; Microbix Biosystems, Toronto, Canada). The resulting pDC516-mHCN2 shuttle plasmid was co-transfected with a 35.5 kb E1-deleted Ad genomic plasmid pBHGfirt E1, 3FLP (AdMax™) into E1-complementing HEK293 cells. The adenoviral
10 construct AdHCN2 was subsequently harvested and CsCl purified.

For adult rat ventricular myocytes, AdHCN2 infection was carried out 2-3 hours after the isolated cells were plated onto coverslips. For neonatal cells, the infection was done on the monolayer culture 1-3 days after plating. In either case, the culture medium was removed
15 from the dishes (35-mm) and the inoculum of 0.2-0.3 ml/dish was added containing AdHCN2. The value of m.o.i. (multiplicity of infection - the ratio of viral units to cells) was 15-100. The inoculum was dispersed over the cells every 20 min by gently "tilting" the dishes so that the cells were evenly exposed to the viral particles. The
20 dishes were kept at 37°C in a CO₂ incubator during the adsorption period of two hours, then the inoculum was discarded and the dishes were washed and refilled with the appropriate culture medium. The dishes remained in the incubator for 24-48 hours before electrophysiological experiments were conducted. In some experiments,
25 an adenoviral construct for GFP (AdGFP) was employed.

Electrophysiologic recording and data analysis

The whole-cell voltage clamp technique was employed to record native

-18-

I_f or expressed I_{HCN2} or I_{HCN4} . Action potentials were recorded in current clamp mode, again using a whole cell patch electrode/Experiments were carried out on cells supervised at 35°C. Extracellular solution contained (mmol/L): NaCl, 140; NaOH, 2.3; MgCl₂, 1; KCl, 5.4; CaCl₂, 1.0; HEPES, 5; glucose, 10; pH 7.4. To record from myocytes expressing native currents (I_f), myocytes expressing HCN2 (I_{HCN2}) or HCN4 (I_{HCN4}), $[K^+]_o$ was increased to 10 mmol/L, and MnCl₂ (2 mmol/L) and BaCl₂ (4 mmol/L) added to the superfusate to eliminate calcium and inward rectifier (I_{K1}) currents.

In some experiments CsCl (4 mmol/L) was used extracellularly to identify the pacemaker current as the Cs-sensitive current. The patch pipette solution included (mmol/L): aspartic acid, 130; KOH, 146; NaCl, 10; CaCl₂, 2; EGTA-KOH, 5; Mg-ATP, 2; HEPES-KOH, 10, pH 7.2. Where indicated, 10 μ mol/L cAMP was included in the pipette solution.

A fast solution changing apparatus expedited the experimental protocols. The pipette resistance was typically 1-3 M. An Axopatch-200B amplifier and pClampS software (Axon Instruments) were used for acquisition and data analysis. The pacemaker current (I_f , I_{HCN2} or I_{HCN4}) was defined as the time-dependent component taken at the end of a hyperpolarizing step to voltages in the range of -35 to -145 mV, while the holding potential was -35 mV unless otherwise indicated. For I_f and I_{HCN2} measurements, the hyperpolarizing test pulses were 3 or 6 sec long throughout the voltage range. To accurately record steady-state currents for the more slowly activating I_{HCN4} , the test voltages varied in length from 6 sec at -125 mV to as long as 60 sec at -55 mV. When recording tail currents, the test pulses were followed by an 8-sec voltage step to -125 mV. In all pacemaker current protocols, each episode ended with a pulse to -5 mV for 0.5 sec to insure full deactivation.

-19-

The activation relation of the native or expressed current can be determined from the steady-state I-V relation. In this case, the reversal potential (V_f) was separately determined from the fully activated I-V relation (27) and used to generate the activation relation ($y = I / (g_{\max} * (V - V_f))$, where g_{\max} is the maximal conductance). This method was used in the initial studies of expression with HCN2 or HCN4 plasmid in neonatal rat ventricular cells (Fig. 2A). Subsequent studies of I_f or I_{HCN2} employed tail current measurements. Tail current, after being plotted against the test voltage, gave the maximum conductance and activation-voltage relation. This relation was normalized by the maximum conductance and fitted with the Boltzmann function ($y = 1 / (1 + \exp((V - V_{1/2}) / K))$) to determine the voltage of half maximum activation ($V_{1/2}$) and slope factor (K). Tail currents were measured at a negative voltage (-125 mV) to avoid contamination by transient outward and other currents at less negative voltages.

The kinetics of activation were determined by a single exponential fit to the early time course of the current activated by hyperpolarizing pulses. Both the initial delay and any late slow activation were ignored. The kinetics of deactivation were determined by a single exponential fit of the time course of the current trace at each test voltage after maximal activation by a conditioning pulse to -125 mV. For both activation and deactivation, the length of the current trace being fit was at least three times as long as the measured time constant to insure accuracy.

Data analysis and statistics

All data are presented as mean \pm S.E.M. Statistical significance was

-20-

examined by f-test for paired and ANOVA for multiple comparisons, and determined at $P < 0.05$.

Results

Comparison of neonatal ventricular myocytes expressing HCN2 and HCN4

5 It has previously been reported that neonatal rat ventricle cells in culture exhibit a small I_f that activates with a threshold voltage around -70 mV (8,10). **Fig. 1A** provides a representative family of current traces of the native I_f in a neonatal rat ventricle cell in culture. A time-dependent inward current component is apparent for
10 voltage steps of -65 mV or more negative. Studies of message levels by RNase protection assay have indicated that both HCN2 and HCN4 are present in the newborn ventricle, with relative message levels of about 5:1 (16). Therefore, each of these isoforms were expressed separately in the neonatal ventricle cultures. As described in
15 Material and Methods, a lipofectin transfection method was employed and the HCN plasmids were co-transfected with pEGFP-C1 to aid in the identification of expressing cells. Expression efficiency was less than 5%, based on the number of visually detected fluorescent cells. More than 90% of fluorescent cells possessed an I_f -like current at
20 least 10 times greater in magnitude than the native current. **Fig. 1B-C** illustrates representative expressed current traces from myocytes transfected with HCN2 and HCN4, respectively. The current magnitude is such as to clearly distinguish the expressed current from the native current. Further, the slower kinetics of the expressed HCN4, compared to HCN2, is apparent (note different time scale in **Fig. 1C**).
25 Slower HCN4 kinetics also have been reported in heterologous expression studies.

-21-

Current records such as those illustrated in Fig. 1 were used to determine the quasi steady-state I-V relation. For the native current and for expressed HCN2, 3-sec voltage steps were sufficient to approximate steady-state at most of the test voltages, although the
5 current did not achieve steady-state at the less negative steps. Significantly longer pulses were required for adequate analysis of HCN4. Reversal potential in each case was separately determined (see Material and Methods), and used to convert the I-V relation to the corresponding activation relation of the native and expressed
10 current. The average activation relations for native current (taken from (28)) and for expressed currents are shown in Fig. 2A. The experiments were conducted on 4-6 day old cultures that had been transfected the same day as cells were dissociated. Neonatal myocytes expressing HCN2 exhibited currents that activated at more negative
15 voltages than those expressing HCN4, and this difference was statistically significant ($V_{1/2}$ of -74.8 ± 1.4 , $n = 17$, and -66.3 ± 2.0 mV, $n = 14$, respectively; $P = 0.001$). Slope factors (K) did not differ (7.7 ± 0.7 and 6.7 ± 0.7 mV; $P = 0.348$). The 8.5 mV difference in midpoint of activation of HCN2 and HCN4, while statistically
20 different, is considerably less than the 40 mV difference (based on threshold measurements) between adult and neonatal ventricle. This suggests that, while a developmental increase in the HCN2/HCN4 ratio might contribute to the age-dependent negative shift in activation of I_f , it cannot fully explain the shift. Fig. 2B compares the
25 activation kinetics of the currents recorded from neonatal ventricular myocytes expressing HCN2 ($n = 6-9$) and HCN4 ($n = 4-5$). For most voltages, HCN4 activation kinetics are markedly slower than those of HCN2. Since HCN4 activates at less negative voltages than HCN2, this cannot be explained by a shift in the voltage dependence

-22-

of activation. Rather, it represents a basic difference in the kinetics of the two isoforms, as has also been reported in heterologous expression experiments (18, 20). The native I_f ($n = 8$) demonstrates activation kinetics intermediate between those of HCN2
5 and HCN4, but the small magnitude of the native current made it impractical to obtain reliable kinetic data at less negative voltages, where the behavior of the two expressed isoforms more markedly diverge.

Comparison of neonatal and adult ventricular myocytes expressing HCN2

10 Since the preceding experiments suggested that an HCN4/HCN2 isoform switch was not likely to fully account for the differences in native I_f between neonatal and adult ventricle, what was next sought was to compare the characteristics of HCN2 (the major ventricular HCN isoform, at the message level, at both ages (16)) when expressed in
15 adult versus neonatal ventricular myocytes. This required maintaining adult ventricle cells in culture for 48 hours. An earlier report indicated that longer culture conditions could result in a marked positive shift in the voltage dependence of activation of native current (9). Therefore what was first compared was native current in
20 acutely dissociated cells with that in cells maintained in culture in serum free medium for 2 days. A voltage clamp protocol that allowed direct construction of the activation relation without the need for a separate determination of the reversal potential, was employed. After a hyperpolarizing step to various test voltages, a
25 second step to -125 mV generated a tail current, the amplitude of which was employed to determine the activation relation. **Fig. 3A-B** provides representative current traces from acutely dissociated and cultured adult rat ventricle cells. In both cases, the cells were

-23-

rod-shaped and quiescent and, as seen in the figure, in both cases the threshold voltage (i.e. first voltage step where a time dependent current is apparent) is more negative than was seen for the native current in the neonate (Fig. 1A). The lipofectin transfection method, with its low efficiency, was inadequate for studies of HCN expression in adult myocytes. Therefore, an adenoviral construct (AdHCN2, see Material and Methods) that contained the mouse HCN2 sequence was prepared. Treatment of the adult cells with this adenoviral construct resulted in expression of high current levels (Fig. 3C, note different scale). In adult ventricular myocytes expressing HCN2, the recorded current activated with a more negative threshold than that previously observed in neonatal cells (Fig. 1B).

Fig. 4A-B compares the activation relation and kinetics of native I_f in acutely dissociated and cultured adult ventricle cells. A 2-day culture period resulted in no significant difference in $V_{1/2}$, although the trend was toward a less negative midpoint after culture (-105.3 ± 2.6 , $n = 12$, vs. -98.7 ± 1.8 mV, $n = 7$, in acutely isolated vs. cultured cells; $P = 0.092$); neither was there a significant difference in slope factor (10.9 ± 1.2 vs. 14.4 ± 1.9 mV). Activation kinetics also did not differ between acutely isolated and cultured adult ventricle. The neonatal data from Fig. 2 are superimposed (dashed lines) to illustrate the neonatal/adult difference in voltage dependence and kinetics of activation of the native I_f . Thus, short-term culture does not significantly alter I_f ; any trend in voltage dependence is modest compared to the effect of development. The neonatal/adult comparison confirms the earlier developmental study that reported an age-dependent difference in voltage dependence of activation (8).

-24-

To compare the characteristics of HCN2 in neonatal and adult ventricular myocytes, the adenoviral construct with both preparations was used. The neonatal data are comparable to the earlier results using the lipofectin method (Fig. 2). Fig. 5A illustrates the average activation relations, from tail current measurements, obtained from myocytes expressing HCN2 in the two culture preparations. It is evident that, when the same protein is expressed in the neonatal and adult myocyte preparations, the resultant current activates at significantly more negative voltages in the adult cells. $V_{1/2}$ values for HCN2 expressed in neonatal and adult myocytes were -77.6 ± 1.6 (n = 24) and -95.9 ± 1.9 mV (n = 13), respectively ($P < 0.001$). In addition, the slope factor (K) also differed significantly (9.8 ± 0.6 vs. 6.5 ± 0.5 mV, $P < 0.001$), reflecting a more shallow voltage dependence in the neonate. Fig. 5B provides data on the voltage dependence of activation/deactivation kinetics for the expressed HCN2. The data were well fit by a standard kinetic model (see legend), and exhibit little difference in the maximal value of activation time constant between the two cultures. However, the voltage dependence of the relation is shifted negative in the adult by an amount (21 mV) that is comparable to the shift in the activation relation (18 mV). Moreover, the relative peaks of the kinetic relations in the two culture preparations are consistent with the previously determined $V_{1/2}$ values (arrows, Fig. 5B). Thus, the difference in the voltage dependence of activation kinetics of HCN2, when expressed in neonatal and adult myocytes, appears related to the voltage dependence of the steady-state activation relation.

Possible Basis for difference between neonatal and adult myocytes expressing HCN2

-25-

In heterologous expression of other currents, the biophysical characteristics of the expressed currents can sometimes depend on the current density achieved (29-32). To determine if the difference in $V_{1/2}$ of HCN2 between neonatal and adult was a result of this type of phenomenon, a linear regression analysis of the data was conducted (Fig. 6). The results indicate that, while there is some correlation of $V_{1/2}$ with current density in the newborn, differences in expression level cannot explain the difference in HCN2 voltage dependence between neonatal and adult myocytes. The neonatal myocytes exhibited a wide range of current density for the expressed current, with a correlation coefficient for $V_{1/2}$ of 0.51 ($P = 0.01$); current density was less variable in the adult, with no correlation with activation midpoint (correlation coefficient 0.043, $P = 0.88$). For current densities common to both preparations (i.e. < 60 pA/pF, Fig. 6 inset) the expressed current in the neonatal myocytes demonstrated a significantly less negative $V_{1/2}$ than in the adult myocytes ($P < 0.001$).

It is well known that both the native I_f and the expressed current respond to cAMP by a phosphorylation independent shift in the voltage dependence of activation (33, 34), although phosphorylation-dependent mechanisms also have been reported (35-37). It is possible that the observed difference in activation of HCN2 in neonatal and adult myocytes simply reflected a different basal cAMP level within the two cells preparations was considered. To test this, the experiments measuring the activation relation of the expressed current with AdHCN2 in neonatal and adult cells were repeated, but this time the experiments included $10 \mu\text{mol/L}$ cAMP in the pipette solution to achieve a maximal positive shift of the current and eliminate any

-26-

differences in intracellular cAMP levels. As seen in Fig. 7, the expressed current shifted positive by a comparable amount in both the neonatal and adult preparations (d
5 large difference in $V_{1/2}$ values persisted. Thus, the age-dependent difference in the voltage dependence of activation of HCN2 does not arise from a difference in basal cAMP level between the two preparations.

Functional effect of overexpression of HCN2

10 The adenoviral construct of HCN2 resulted in expression of a large current in the majority of cells (at least 90% of cells patch clamped). Given the relatively positive activation of the expressed current in the neonatal cells, placing it within the physiologic range of voltages, it was next determined if overexpression of HCN2
15 resulted in a change in spontaneous rate of these cultures. These experiments were conducted using monolayer cultures of synchronously beating cells, with a whole cell patch electrode recording from one cell of the contiguous monolayer. The control (non-infected) cultures beat spontaneously, with a mean rate of 48.4 ± 4.4 beats per min
20 (bpm, $n = 17$). There was little or no diastolic depolarization between action potentials and the cycle length tended to vary from beat to beat (Fig. 8A). The maximum diastolic potential (MDP) was - 65.2 ± 1.8 mV ($n = 17$). In contrast, the cultures infected with AdHCN2 exhibited a more regular and faster rhythm (Fig. 8B), with
25 mean rate of 88.0 ± 5.4 bpm ($n = 16$). Further, these cultures exhibited a marked diastolic depolarization and a less negative MDP (Fig. 8C). The differences in frequency, phase 4 slope, and MDP were statistically significant ($P < 0.05$). Cultures infected with AdGFP

-27-

(frequency: 45.8 ± 4.7 bpm; MDP: -59.5 ± 2.4 mV; $n = 6$) did not differ from uninfected control cultures, but did differ significantly from AdHCN2 infected cells.

The adult cultures did not beat spontaneously, either under control conditions or after infection with AdHCN2. This was not surprising, given the relatively negative activation relation of the expressed current in the adult cells. However, Ranjan et al. (38) have proposed that native I_f in the adult mammalian ventricle contributes to anode break stimulation. If sufficiently strong, the hyperpolarizing stimulus activates I_f . The resultant inward tail current, combined with the voltage dependent block of I_{K1} , then causes the membrane potential to overshoot the resting potential in a depolarizing direction upon termination of the stimulus, leading to excitation. Therefore, the susceptibility to anode break excitation of control adult cultures and those infected with AdHCN2 was compared. Using a 20-msec stimulus, the maximal negative potential achieved for a threshold anodal stimulation was measured. Also measured was the I_f density at the end of a 2-sec voltage step up to -125 mV in the same cells. **Fig. 9** illustrates that the infected cells more readily exhibited anode break excitation. **Fig. 9A** illustrates representative control (left, with stimulus time course above) and infected (right) traces of anodal stimuli and resulting action potential upstrokes. The delay between the end of the anodal stimulus and the action potential threshold was not statistically different between control and infected cells (45 ± 10 vs. 58 ± 9 ms, $P > 0.05$). **Fig. 9B** graphs the relation between maximal negative potential at threshold and I_f or I_{HCN2} density for control (unfilled symbol) and infected (filled symbol) cells. Control cells exhibited an inverse correlation between

-28-

the maximal negative voltage required for anodal excitation and I_f density (Fig. 9B, inset), supporting the hypothesis that native I_f contributes to anode break excitation. In comparison, in infected cells it was sufficient to hyperpolarize the membrane to approximately -80 mV, i.e. the threshold for expressed HCN2 current. Anode break threshold was independent of expressed current density, indicating that the expressed current was large enough in all infected cells to generate a sufficient overshoot for achieving excitation at I_{HCN2} threshold. When required stimulus energy was calculated, as the integral of the area from start of the stimulus to threshold of the action potential, there was a significant difference between control and AdHCN2 infected cells (3140 ± 279 , $n = 10$, vs. 2149 ± 266 mV•ms, $n = 12$; $P < 0.05$). Neither the required stimulus energy nor the spontaneous rate of cells infected with AdGFP differed from those of control cells (data not shown), indicating that this was not simply an effect of the adenoviral infection. In addition, resting potential did not differ between control, AdHCN2 and AdGFP infected myocytes (data not shown).

Discussion

This study investigated if the distinct activation voltage of I_f in neonatal and adult ventricle was the result of a pronounced difference in the biophysical properties of the HCN2 and HCN4 isoforms when expressed in ventricular myocytes, or whether this developmental difference was due to an influence of the maturational state of the myocyte on an individual isoform, specifically HCN2. The results indicate that while HCN4, which is more prevalent in neonatal than adult ventricle, does activate at less negative voltages than HCN2 when expressed in the neonatal ventricle, this isoform effect

-29-

is modest. In comparison, when the HCN2 isoform is separately expressed in neonatal and adult ventricular myocytes, the midpoints of activation differ by 18 mV, compared to a difference of 22 mV in the midpoints of activation of the native I_f current in the neonate and adult ventricle in culture. Thus, the developmental difference in pacemaker current voltage dependence under these experimental conditions is largely accounted for by an effect of the myocyte maturational state on the HCN2 isoform, rather than an HCN4/HCN2 isoform switch. Further, this difference in activation voltage results in a marked difference in the physiologic impact of expressed HCN2 current, due to the relative position of the current threshold with respect to the maximum diastolic potential as a function of age.

In investigating this question, first was compared the biophysical characteristics of mouse HCN2 and HCN4 expressed in neonatal rat ventricular myocytes, rather than in a heterologous mammalian expression system such as HEK293 cells. As with prior heterologous expression studies, these data indicate that an inherent difference in the voltage dependence of HCN2 and HCN4, when expressed in myocytes, does not by itself account for the age-dependent difference in voltage dependence. At both ages, HCN2 is the dominant isoform based on RNase protection, although the relative ratio of HCN2/HCN4 message increases developmentally (16). The 9-mV negative shift of HCN2 activation, relative to HCN4 (-75 and -66 mV, respectively, using the lipofectin transfection method) in neonatal myocytes is far less than the developmental difference in native current activation. In addition, the kinetics of activation of the native I_f are faster in the neonate than adult, while the activation kinetics of HCN4 are slower than those of HCN2. Thus, a dominant contribution of HCN4 in

-30-

the neonate, changing to a dominant contribution of HCN2 in the adult, is inadequate to explain the developmental difference in either activation voltage or activation kinetics. It should be noted, however, that this does not preclude an isoform switch as a necessary or contributory component of the developmental change in voltage dependence. It could be that HCN4 would activate at markedly less negative voltages in adult as well as neonatal ventricle, i.e. that only HCN2 is sensitive to the maturational state of the myocyte.

While resolution of this question awaits preparation of an HCN4 adenoviral construct for efficient infection of adult myocytes, it seems unlikely given existing heterologous expression results concerning HCN4, which do not suggest that HCN4 is inherently positive. Admittedly, it is difficult to compare activation voltages between studies, since even with the same preparation considerable differences arise between laboratories as a result of variations in cell preparation and/or recording protocols. Still, it is interesting that HCN4 expression in the neonatal ventricle is much less negative than in any reported mammalian expression study. A midpoint of -66 mV was observed, whereas in other mammalian expression studies reported values ranging from -80 to -109 mV for this isoform (17-20). HCN2 in the neonatal ventricle also activates at less negative voltages than in other mammalian systems, with a midpoint of -78 mV (by tail measurement with adenoviral infection) in the present study, compared to values ranging from -83 to -97 mV (18-20, 39). In those cases where activation voltage of HCN2 and HCN4 were measured in the same study, HCN2 activated either slightly less negatively (18), equivalently (19) or slightly more negatively (20) than HCN4. Thus, while the results largely agree with other studies that reported only

-31-

a modest difference in activation voltage between HCN2 and HCN4, in general what was observed was less negative activation of both isoforms in the neonatal ventricle, compared to other mammalian expression systems. This suggests that perhaps the neonatal myocyte provides a unique environment, relative to alternative expression systems, allowing for less negative activation. However, at least one oocyte expression study (40) reported HCN2 activation equivalent to that in the neonatal ventricle, with a midpoint of -78 mV, suggesting that other systems also are capable of expressing HCN2 with less negative voltage dependence.

While it is not clear whether it is the neonatal or the adult environment which is unique (or rather they are merely two distinct points on a continuum), it is clear that HCN2 exhibits markedly different voltage dependence when expressed in the two cell preparations, and that this parallels the developmental difference in native I_f . Under these experimental conditions, the midpoint of activation of native current in newborn and adult ventricle differed by approximately 22 mV, less than the previously reported difference in threshold value of approximately 40 mV (8). A portion of the difference may result from the 48-hour culture period, since acutely isolated adult myocytes had a midpoint value of activation that was 6 mV more negative. Although this was not a statistically significant difference, it is in keeping with an earlier study that found that extended culture under conditions that caused morphological dedifferentiation of adult myocytes resulted in a marked positive shift of activation voltage (9). In addition, the earlier developmental study specifically used adult epicardial myocytes (8), while the present study used the whole ventricle of the adult heart

-32-

to obtain a higher yield of viable cells for culture. A gradient of I_f activation, with epicardium more negative than endocardium, has been observed in the canine heart (41). If a similar gradient exists in adult rat ventricle then this also could contribute to the less negative adult values observed in the present study. It remains to be determined if expressed HCN2 current would activate at even more negative voltages if expressed in epicardial myocytes.

The actual midpoints of activation of native I_f in ventricle were -77 and -99 mV in neonate and adult, respectively, compared to values for HCN2 of -78 and -96 mV in these two preparations. Thus, HCN2 activation largely explains the voltage dependence of the native I_f . The difference in activation between neonatal and adult ventricle is not secondary to differences in cAMP levels, since saturating cAMP in the pipette shifts the voltage dependence of HCN2 by a comparable amount in the neonate and adult myocytes (17 and 14 mV, respectively). Beyond elimination of basal cAMP as a factor, the basis for the age-dependent difference in HCN2 voltage dependence when expressed in myocytes is unclear. The range of voltage dependence reported for I_f in different cardiac regions or as a function of age or disease is pronounced, and may reflect a combination of mechanisms. Studies of other channels have identified a number of factors that can alter the biophysical properties of native or expressed current, including beta subunits (42, 43), local membrane composition (44), cytoskeletal interactions (45), phosphorylation/dephosphorylation (35, 36, 46) and other post-translational modifications such as truncation (47). The extent to which any of these mechanisms contribute to the variation in voltage dependence of I_f or I_{HCN2} is unknown. In this context, it is

-33-

interesting that when native I_f is studied in a cell free macro patch activation shifts markedly negative, but treatment of the intracellular face of the patch with pronase shifts activation back in the positive direction by 56 mV (48). In addition, when a large
5 portion of the HCN2 C-terminal that includes the cyclic nucleotide binding domain is deleted, activation shifts positive by 24 mV (49). From these results one can speculate that interactions between cytoplasmic elements of the HCN protein contribute to more negative activation, but that these interactions are minimized in the intact
10 cell, perhaps due to the presence of cytoskeletal elements, a beta subunit or other factors. The extent to which any of these factors actually contribute to the regional or developmental variation in activation voltage remains to be determined. However, if this reasoning is correct, then the factor(s) that contribute to the less
15 negative activation of HCN2 in the neonate do not appear to be substrate limited, since no negative shift in activation voltage (and in fact a slight positive trend) at expression levels that were 2-3 orders of magnitude greater than that typical of native current in this preparation was observed.

20 The kinetic characteristics of the native current in neonate and adult ventricle also are largely explainable by HCN2, though perhaps not entirely. In the neonate, native current activates with kinetics that are intermediate-between those of HCN2 and HCN4 expressed in these same cells. When the full activation/deactivation relation of
25 expressed HCN2 is compared in neonate and adult, the difference is largely attributable to the difference in voltage dependence of activation. Thus, there does not appear to be an effect of maturational state of the myocyte directly on activation kinetics of

-34-

expressed current, independent of the effect on voltage dependence of activation. However, native I_f kinetics in adult appear slower than expressed HCN2 kinetics (compare Figs. 4B and 5B).

Not surprisingly, expressing high levels of HCN2 in a neonatal culture results in a marked increase in spontaneous rate. This is accompanied by a less negative maximum diastolic potential and more pronounced phase 4 slope. The maximum diastolic potential in the HCN2 infected culture corresponds to the threshold voltage of the HCN2 current, indicating that even threshold levels of expressed current are sufficient to balance the contribution of I_{K1} (which is small in neonatal cultures (50)). Expressing HCN2 in adult myocytes does not result in automaticity, either because of the more negative activation range in the adult cells or the greater I_{K1} density at this age. However, it does increase the susceptibility to anode break excitation. In HCN2 infected cultures of adult cells, the maximal negative voltage required during anodal stimulation in order to exhibit anode break excitation corresponds to the threshold voltage of the HCN2 current. Thus, the physiologic impact of overexpression of the HCN gene family in myocardium depends on the threshold voltage of the expressed current. This threshold voltage, and therefore the physiologic impact of HCN overexpression, to some extent depends on which isoform is expressed (i.e. HCN2 vs HCN4 in neonate). However, effect also is context dependent - with a distinct result, depending on the maturational state of the target tissue. For the same reason, effect is likely to depend on the cardiac region in which the channel is expressed and the disease state of the tissue, since native current is markedly affected by these factors. This has obvious implications for any future efforts to alter cardiac rhythm through

-35-

the regional overexpression of selective HCN isoforms. It suggests rate can be enhanced by increasing current level, if the expressed current activates at an appropriate threshold voltage in the target tissue. As further insight into the mechanisms regulating the voltage dependence of this gene family is gained, it may be possible to control both the level of current and its activation voltage.

EXPERIMENTAL DETAILS EXAMPLE 2:

MiRP1: A Beta Subunit for the HCN Ion Channel Subunit Family Enhances Expression and Speeds Kinetics.

The HCN (Hyperpolarization-activated Cyclic Nucleotide gated) family of ion channel subunits has been identified as the molecular correlate of the currents I_f in heart and I_h and I_q in neurons (14,15,26). However, a number of ion channels are heteromultimers of a large α subunit (like the HCN family members) and smaller β subunits. The cardiac delayed rectifiers I_{Kr} (51) and I_{Ks} (52) are examples of this basic principle. Their α subunits derive from the ERG and KCNQ families respectively, but both also contain β subunits from a family of single transmembrane spanning proteins called minK and MiRPs (minK related peptides).

MiRP1 enhances expression and speeds the kinetics of activation of the HCN family of channel subunits. RNase protection assays (RPAs) show that MiRP1 mRNA is prevalent in the primary cardiac pacemaking region, the sinoatrial node, and barely detectable in ventricle. Coimmunoprecipitation indicates that MiRP1 forms a complex with HCN1. Taken together, these results suggest that MiRP1 is a β subunit for

-36-

the HCN family of ion channel protein subunits, and that it is likely to be an important regulator of cardiac pacemaker activity.

A. Heterologous expression in *Xenopus* oocytes

cRNA encoding mouse HCN1 or HCN2, rat MiRP1 with or without an HA tag
5 at the carboxy-terminal and rat minK were transcribed by using the
mMessage mMachine kit (Ambion, Austin, TX). *Xenopus laevis* oocytes
were isolated, injected with 2-5 ng (50-100 nl) of cRNA, and
maintained in Barth medium at 18°C for 1-2 days. For experiments
using both HCN1 or HCN2 and MiRP1 or minK, the respective cRNAs were
10 injected in 1:0.04-1 ratio. Electrophysiologic studies on oocytes
employed the two-microelectrode voltage clamp. The extracellular
recording solution (OR2) contained: 80 mM NaCl, 2 mM KCl, 1 mM MgCl₂,
and 5 mM Na-HEPES (pH 7.6). Group data are presented as means ± SEM.
Tests of statistical significance for midpoint and slope of
15 activation curves were performed using unpaired Student's t-tests.
P < .05 is considered significant.

B. RNase Protection Assays

The procedures for the preparation of total RNA from rabbit heart
tissues and the performance of the RNase protection assays was
20 similar to those described previously (53). Brain total RNA was
obtained commercially from Clontech, and total RNA was isolated from
left ventricle, right atrium and brain using SV Total RNA System
(Promega). For each experiment 2 µg of total RNA was used. A
cyclophilin probe was used in each experiment as an internal control
25 over sample loss. RNA expression was quantified directly from dried
RNase protection assay gels using a Storm phosphorimager (Molecular
Dynamics), normalized to the cyclophilin signal in each lane. The

-37-

MiRP1 signal consisted of two protected fragments in each rabbit tissue where MiRP1 was detected. The presence of two bands is likely the result of the degenerate PCR primers, based on mouse and human sequences, used for the cloning of the RPA probes. The combined
5 intensity of both bands was used in the quantification.

C. Protein Chemistry

Membrane protein preparation. All steps were performed in ice. 25 oocytes were washed with Ringer solution (96 mM NaCl, 1.8 mM CaCl₂, 5 mM Hepes (pH 7.4) and lysed by vortexing with 1 ml lysis buffer 1
10 (7.5 mM Na₂HPO₄ (pH 7.4), 1 mM EDTA) with protease inhibitors (aprotinin, leupeptine and pepstatin A, 5 µg/ml of each, and 1 mM PMSF). The lysate was centrifuged for 5 min at 150xg to remove yolk proteins and subsequently for 30 min at 14000xg. The membrane pellet was washed with lysis buffer 1 and resuspended in 1 ml of lysis
15 buffer 2 (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 50 mM NaF, 50 mM Na pyrophosphate, 100 mM KH₂PO₄, 10 mM Na molybdate, 2mM Na orthovanadate, 1% triton X-100, 0.5% NP40) with the same set of protease inhibitors as lysis buffer 1. Protein concentration of the membrane fractions was determined by the Lowry method.

20 **Immunocytochemistry.** For western blot analysis, proteins associated with oocyte membrane fractions were separated on 10% SDS/PAGE (for HCN1) or on 16.5% tricine-SDS/PAGE (for MiRP1 (54)), and electroblotted to Hybond ECL™ nitrocellulose membranes (Amersham Pharmacia Biotech). Blocking and antibody incubations were done in PBST. The rabbit HCN1
25 antibodies (Quality Controlled Biochemicals) and the rat anti-HA high affinity antibodies (Roche Molecular Biochemicals) were used at 1:5000 and at 1:500 dilution, respectively. Secondary anti-rabbit

-38-

(Kirkegaard Perry Laboratories, Maryland, USA) and anti-rat Ig-POD, Fab fragments (Boehringer Mannheim Biochemica) coupled to horseradish peroxidase were used at 1:10000 or 1:2000 dilution, respectively. The immunoreactive protein bands were visualized using Lumi-Light^{PLUS} Western Blotting Substrate (Roche Molecular Biochemicals). The immunoprecipitation reactions were performed using 250 μ g of membrane protein fractions and 10 μ l of HCN1 antibodies cross-linked to protein A/G PLUS-Agarose (Santa Cruz Biotechnology, Inc.) with dimethylpimelimidate.

10 Results

Xenopus oocytes were employed as a heterologous expression system and the expression of HCN1 and HCN2 individually and coexpressed with either minK (the minimal K channel protein, the first identified member of the single transmembrane spanning proteins family) or with MiRP1 was examined. The results are shown in figure 10. Both HCN1 (Fig. 10A) and HCN2 (Fig. 10D) express a small current when injected alone. Coexpression of either HCN1 (Fig. 10B) or HCN2 (Fig. 10E) with minK results in similar, low levels of current expression. However, a much larger current is observed when either HCN1 (Fig. 10C) or HCN2 (Fig. 10F) is coexpressed with MiRP1. Injection of MiRP1 by itself did not induce a current nor did injection with 100 nl of H₂O (not shown). The complete set of results for the expression studies of HCN1 and HCN2 with or without minK and MiRP1 are illustrated in Fig. 10G and Fig. 10H. The maximal conductance is calculated by dividing the current onset at the most negative potential by the driving force (the reversal potential was measured in each oocyte). The results demonstrate an almost threefold enhancement of HCN1 conductance when HCN1 is coexpressed with MiRP1, whereas MiRP1 enhances expression of

-39-

HCN2 by more than fivefold. Coexpression of either HCN1 or HCN2 with minK does not enhance HCN1 or HCN2 expression. Thus the enhancement of expression is specific for MiRP1.

Next was examined the gating properties of MiRP1 coexpressed with either HCN1 or HCN2. The results are presented in figure 11. Isochronal activation curves were constructed from tail currents recorded at -10mV in response to 3 (for HCN1) or 8 (for HCN2) second long hyperpolarizing test pulses. The results demonstrate no significant difference in midpoint but statistically indicate a shallower slope for the activation of HCN channels coexpressed with MiRP1 (Figs. 11A and 11B, see figure legends for details).

Also, the kinetics of activation and deactivation was examined (see Fig. 11C-Fig. 11F). Raw data are shown for activation of both HCN1 (Fig. 11C) and HCN2 (Fig. 11D), MiRP1 decreases the time constant of activation. The average of all the results on activation and deactivation (indicated by the encircled box) are provided in Figs. 11E and 11F. Coexpression with MiRP1 accelerates both processes.

The rectification properties of HCN1 or HCN2 expressed with or without MiRP1 were also studied. Coexpression of either HCN1 or HCN2 with MiRP1 did not alter the linearity of the fully activated current-voltage relationship (not shown).

Previous studies examining the potential role of MiRP1 in generating I_{Kr} employed Northern Blot analysis to demonstrate the presence of MiRP1 mRNA in whole rat heart (51). If MiRP1 also regulates i_f current expression in vivo, mRNA for MiRP1 should be prominent in regions where i_f currents are large. RNase protection assays was employed to quantify the distribution of MiRP1 transcripts in SA

-40-

node, right atrium and ventricle of the rabbit heart. The results are provided in figure 12. MiRP1 transcript levels are highest in the SA node, atrial levels are about 40% of those in SA node, while ventricular levels are barely detectable (< 4% of SA node).

5 Here, it was demonstrated that a complex probably exists between members of the HCN family and MiRP1, which shows that MiRP1 could be a β subunit for the HCN family. This question was chosen to be pursued with HCN1 as there are antibodies (see Methods) against this family member.

10 The HCN1 antibody recognizes a single polypeptide with an apparent molecular mass of 145 kDa (possibly glycosylated (55)). MiRP1, HA epitope-tagged at the carboxy-terminal end, was recognized by anti-HA high affinity antibodies as a 13.5 kDa band. Both proteins were localized in the membrane fraction, and protein expression was
15 enhanced (about 2-fold) when they were co-expressed together (Fig. 13A and 13B).

To test whether a complex of HCN1 and MiRP1 might exist in a heterologous expression system, coimmunoprecipitation experiments were performed using membrane fractions of oocytes injected with HCN1
20 alone, MiRP1 alone, or with both cRNAs, Figure 13C shows the immunoprecipitation products tested by western blot analysis. The presence of MiRP1 in the anti-HCN1 immunoprecipitate only for oocytes injected by both HCN1 and MiRP1 cR
oocytes injected by one of these mRNAs, indicates that MiRP1 was
25 pulled down by anti-HCN1 antibody most likely because it was complexed with HCN1.

The results demonstrate that the proteins are colocalized as a

-41-

complex in the membrane and enhance each other's expression. This strongly suggests that MiRP1 is a β subunit for the HCN family of ion channel subunits.

Discussion

5 MiRP1 is a member of a family of single transmembrane spanning proteins that have been demonstrated to alter expression and serve as a β subunit of both KCNQ (minK) and ERG (MiRP1) family members (51,53). In these previous studies, as in this study, the minK family member altered gating and was demonstrated to be a beta subunit by
10 co-immunoprecipitation.

Here, it has been shown that minK does not affect the properties of HCN1 and HCN2 channels expressed in *Xenopus* oocytes. MiRP1, on the other hand, dramatically enhances the current expression of both HCN subunits and hastens the kinetics of current activation and
15 deactivation. A speeding of deactivation kinetics is also seen when MiRP1 associates with HERG to form I_{Kr} (51). The data presented here also show, that MiRP1 and HCN1 probably form a complex in the membrane.

Pacemaker activity in the rabbit sinus node is generated by a net
20 inward current of only a few pA (56). This net inward current is due to the balance of inward and outward currents more than an order of magnitude larger. Although the biophysical properties of each of the component currents is known, how this fine balance is achieved remains unknown. The results presented here show that a single beta
25 subunit may control the expression of two important pacemaker currents, the outward I_{Kr} , and the inward I_f . If this is the case, it

-42-

is possible that MiRP1 serves as an important regulator of cardiac pacemaker rate.

Although one preferred embodiment of the invention is described, the invention is not so limited, as variations and modifications will
5 occur to those skilled in the art.

The scope of the invention is determined by way of the appended claims.

REFERENCES

1. DiFrancesco D: The cardiac hyperpolarizing-activated current, I_f : Origins and developments. *Prog. BiophysMol. Biol.* Vol. 46, No. 3, 1985, pages 163-183.
- 5 2. Zhou Z and Lipsius SL: Effect of isoprenaline on I_f current in latent pacemaker cells isolated from cat right atrium: ruptured vs. perforated patch whole-cell recording methods. *Pflugers Arch.* Vol. 423, No.5 Pt. 6, June 1993, pages 442-447.
- 10 3. Thuringer D, et al.: A hyperpolarization-activated inward current in human myocardial cells. *JmolCell. Cardiol.* Vol. 24, No. 5, May 1992, pages 451-455.
- 15 4. Porciatti F, et al.: Block of the pacemaker current I_f in single human atrial myocytes and the effect of beta-adrenoceptor and Al-adenosine receptor stimulation. *Br Jpharmacol.* Vol. 122, No. 6, February 1991, pages 963-969.
5. Yu H, et al.: Pacemaker current exists in ventricular myocytes. *Circ. Res.* Vol. 72, No. 1, January 1993, pages 232-236.
- 20 6. Cerbai E, et al.: The properties of the pacemaker current I_f in Human Ventricular Myocytes are modulaed by Cardiac Disease. *Jmol. Cell Cardiol.* Vol. 33, No. 3, March 2001, pages 441-448.
7. DiFrancesco D: Generation and control of cardiac pacing: the pacemaker current. *Tends Cardiovasc. Med.* Vol. 1, 1991, pages 250-255.
- 25 8. Robinson RB, et al.: Developmental change in the voltage dependence of the pacemaker current, I_f , in rat ventricle cells.

-44-

Pflugers Arch. Vol. 433, 1991, pages 533-535.

9. Fares N, et al.: Characterization of a hyperpolarization-activated current in dedifferentiated adult rat ventricular cells in primary culture. *J. Physiol.* Vol. 506, No. 1, January 1, 1998, pages 73-82.
5
10. Cerbai E, et al.: Influence of postnatal-development on I_f occurrence and properties in neonatal rat ventricular myocytes. *Cardiovasc. Res.* Vol. 42, No. 2, May 1999, pages 416-423.
11. Cerbai E, et al.: Characterization of the hyperpolarization-activated current, I_f , in ventricular myocytes isolated from hypertensive rats. *J. Physiol.* Vol. 481, No. 3, Dec 15, 1994, pages 585-591.
10
12. Cerbai E, et al.: Characterization of the hyperpolarization-activated current, I_f , in ventricular myocytes from human failing heart. *Circulation.* Vol. 95, No. 3, February 4, 1997, pages 568-571.
15
13. Santoro B, et al.: Interactive cloning with the SH3 domain of N-src identifies a new brain specific ion channel protein, with homology to Eag and cyclic nucleotide-gated channels. *Proc. Natl. Sci. USA.* Vol. 94, No. 26, December 23, 1997, pages 14815-14820.
20
14. Ludwig A, et al.: A family of hyperpolarization-activated mammalian cation channels. *Nature.* Vol. 393, No. 6685, June 11, 1998, pages 587-591.
15. Santoro B, et al.: Identification of a gene encoding a
25

-45-

hyperpolarization-activated pacemaker channel of brain. *Cell*. Vol. 93, No. 5, May 29, 1998, pages 717-729.

16. Shi W, et al.: Distribution and Prevalence of hyperpolarization-activated cation channel (HCN) mRNA Expression in Cardiac Tissues. *Circ. Res.* Vol. 85, No. 1, July 9, 1999, pages e1-e6.
17. Ishii TM, et al.: Molecular characterization of the hyperpolarization-activated cation channel in rabbit heart sinoatrial node. *J. Biol. Chem.* Vol. 264, No. 18, April 30, 1999, pages 12835-12839.
18. Ludwig A, et al.: Two pacemaker channels from human heart with profoundly different activation kinetics. *EMBO J.* Vol. 18, No. 9, May 4, 1999, pages 2323-2329.
19. Moosmang S, et al.: Cellular expression and functional characterization of four hyperpolarization-activated pacemaker channels in cardiac and neuronal tissues. *Eur. J. Biochem.* Vol. 268, No. 6, March 2001, pages 1646-1652.
20. Altomare C, et al.: Allosteric voltage-dependent gating of HCN channels. *Biophys. J.* Vol. 80, 2001, pages 241a.
21. Protas L, et al.: Chronic neuropeptide Y exposure increases L-type Ca current in neonatal rat cardiomyocytes. *Am. J. Physiol.* Vol. 277, No. 3 Pt. 2, September 1999, pages H940-H946.
22. Kuznetsov V, et al.: β 2-adrenergic receptor actions in neonatal and adult rat ventricular myocytes. *Circ. Res.* Vol. 76, No. 1, January 1995, pages 40-52.

-46-

23. Ellingston O, et al.: Adult rat ventricular myocytes cultured in defined medium: phenotype and electromechanical function. *Am. J. Physiol.* Vol. 265, No. 2 Pt. 2, August 1993, pages H747-H754.
- 5 24. Ng P, et al.: An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. *Hwn.Gene Ther.* Vol. 11, No. 5, March 20, 2000, pages 693-699.
25. He TC, et al.: A simplified system for generating recombinant adenoviruses. *Proc. Natl. Acad. Sci. USA.* Vol. 95, No. 5, March 10 3, 1998, pages 2509-2514.
26. Santoro B, et al.: The HCN gene family: molecular basis of the hyperpolarization-activated pacemaker channels. *Ann. NY Acad. Sci.* Vol.868, April 30, 1999, pages 741-764.
27. Accili EA, et al.: Properties and modulation of I_f in newborn 15 versus adult cardiac SA node. *Am. J. Physiol.* Vol. 272, 1991, pages H1549-H1552.
28. Qu J, et al.: Sympathetic innervation alters activation of pacemaker current (I_f) in rat ventricles. *J. Physiol.* Vol. 526, No. 3, August 1, 2000, pages 561-569.
- 20 29. Cui J, et al.: Gating of I_{sK} expressed in *Xenopus* oocytes depends on the amount of mRNA injected. *Gen. Physiol.* Vol. 104, No. 1, July 1994, pages 87-105.
30. Guillemare E, et al.: Effects of the level of mRNA expression on biophysical properties, sensitivity to neurotoxins, and 25 regulation of the brain delayed-rectifier K^+ channels $Kv1.2$.

-47-

- Biochemistry*. Vol. 31, No. 49, December 15, 1992, pages 12463-12468.
31. Honore E, et al.: Different types of K⁺ channel current are generated by different levels of a single mRNA. *EMBO J*. Vol. 11, No. 7, July 1992, pages 2465-2471.
32. Moran O, et al.: Level of expression controls modes of gating of a K⁺ channel. *FEBS Lett*. Vol. 302, No. 1, May 4, 1992, pages 21-25.
33. DiFrancesco D, et al.: Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. *Nature*. Vol. 351, No. 6322, May 9, 1991, pages 145-147.
34. Kaupp UB, et al.: Molecular diversity of pacemaker ion channels. *Annu, Rev. Physiol*. Vol. 63, 2001, pages 235-257.
35. Chang F, et al.: Effects of protein kinase inhibitors on canine Purkinje fibre pacemaker depolarization and the pacemaker current I_f. *J. Physiol*. Vol. 440, 1991, pages 367-384.
36. Yu H, et al.: Phosphatase inhibition by calyculin A increases I_f in canine Purkinje fibers and myocytes. *Pflugers Arch*. Vol. 422, No. 6, March 1993, pages 614-616.
37. Accili EA, et al.: Differential control of the hyperpolarization-activated current (I_f) by intracellular cAMP and phosphatase inhibition. *J. Physiol*. Vol. 491, 1996, pages 115.
38. Ranjan R, et al.: Mechanism of anode break stimulation in the heart. *Biophys. J*. Vol. 74, No. 4, April 1998, pages 1850-1863.

-48-

39. Moroni A, et al.: Kinetic and ionic properties of the human HCN2 pacemaker channel. *Pflugers Arch.* Vol. 439, No. 5, March 2000, pages 618-626.
40. Santoro B, et al.: Molecular and functional heterogeneity of hyperpolarization-activated pacemaker channels in the mouse CNS. *J neurosci.* Vol. 20, No. 14, July 15, 2000, pages 5264-5275.
41. Shi W, et al.: The distribution and prevalence of HCN isoforms in the canine heart and their relation to the voltage dependence of I_f . *Biophys. J.* Vol. 78, 2000, pages 353A.
42. Melman YF, et al.: Structural determinants of KvLQT1 control by the KCNE family of proteins. *J Biol Chem.* Vol. 276, No. 9, March 2, 2001, pages 6439-6444.
43. Tinel N, et al.: KCNE2 confers background current characteristics to the cardiac KCNQ1 potassium channel. *EMBO J.* Vol. 19, No. 23, December 1, 2000, pages 6326-6330.
44. Martens JR, et al.: Differential targeting of Shaker-like potassium channels to lipid rafts. *Biol Chem.* Vol. 275, No. 11, March 17, 2000, pages 7443-7446.
45. Chauhan VS, et al.: Abnormal cardiac Na(+) channel properties and QT heart rate adaptation in neonatal ankyrin(B) knockout mice. *Circ. Res.* Vol. 86, No. 4, March 3, 2000, pages 441-447.
46. Walsh KB, et al.: Distinct voltage-dependent regulation of heart-delayed I_K by protein kinases A and C. *Am. J. Physiol.* Vol. 261, No. 6 Pt. 1, December 1991, pages C1081-C1090.

-49-

47. Gerhardstein BL, et al.: Proteolytic processing of the C terminus of the alpha (1C) subunit of L-type calcium channels and role of a proline-rich domain in membrane tethering of proteolytic fragments. *J Biol. Chem.* Vol. 275, No. 12, March 24, 2000, pages 8556-8563.
48. Barbuti A, et al.: Action of internal pronase on the f-channel kinetics in the rabbit SA node. *J. Physiol.* Vol. 520, No. 3, November 1, 1999, pages 737-744.
49. Wainger BJ, et al.: Domains involved in cyclic nucleotide modulation of hyperpolarization-activated HCN channels. *Nature.* In Press, 2001.
50. Wahler GM: Developmental increases in the inwardly rectifying potassium current of rat ventricular myocytes. *Am. J. Physiol.* Vol. 262, No. 5 Pt. 1, May 1992, pages C1266.
51. Abbott GW, et al.: MiRP1 forms I_{Kr} potassium channels with HERG and is associated with cardiac arrhythmia. *Cell.* Vol. 97, No. 2, April 16, 1999, pages 175-187.
52. Sanguinetti MC, et al.: Coassembly of KvLGQT1 and minK (I_{SK}) proteins to form cardiac I_{SK} potassium channels. *Nature.* Vol. 384, No. 6604, November 7, 1996, pages 80-83.
53. Dixon JE and McKinnon D: Quantitative analysis of potassium channel expression in atrial and ventricular muscle of rats. *Circ. Res.* Vol. 75, No. 2, August 1994, pages 252-260.
54. Schlagger H and von Jagow G: Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for separation of proteins

-50-

in the range from 1 to 100 Kda. *Analytical Biochem.* Vol. 166, No. 2, November 1, 1987, pages 368-379.

55. Hansen JE, et al.: Prediction of O-glycosylation of mammalian proteins: Specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. *Biochem. J.* Vol. 308, No. 3, June 15, 1995, pages 801-813.
56. Vassalle M, et al.: Pacemaker channels and cardiac automaticity In "Cardiac Electrophysiology. From Cell to Bedside", Eds. Zipes D and Jalife WB Saunders Co. Philadelphia, PA, 2000, pages 94-103.

-51-

What is claimed:

1. A method of treating a cardiac condition in a subject which comprises contacting a cell of the heart of the subject with a compound in an amount sufficient to increase the current
5 expression of the cell, thereby treating the cardiac condition in the subject.
2. The method of claim 1, wherein the current is the pacemaker current.
3. The method of claim 1, wherein the subject is a mammal.
- 10 4. The method of claim 3, wherein the mammal is a human.
5. The method of claim 1, wherein the cell is a cardiac myocyte.
6. The method of claim 1, wherein the cardiac condition is a cardiac rhythm disorder.
7. The method of claim 6, wherein the cardiac rhythm disorder is
15 selected from a group consisting of conductive block, complete atrioventricular block, incomplete atrioventricular block and sinus node dysfunction.
8. The method of claim 1, wherein the compound comprises a nucleic acid which encodes MiRP1.
- 20 9. The method of claim 1, wherein the compound comprises a nucleic acid which encodes an HCN channel.
10. The method of claim 9, wherein the HCN channel is HCN1.
11. The method of claim 9, wherein the HCN channel is HCN2.

-52-

12. The method of claim 9, wherein the HCN channel is HCN4.
13. The method of claim 1, wherein the compound comprises nucleic acids which encodes MiRP1 and a HCN channel.
14. The method of claim 13 wherein the HCN channel is HCN1.
- 5 15. The method of claim 13 wherein the HCN channel is HCN2.
16. The method of claim 13 wherein the HCN channel is HCN4.
17. The method of claim 1, wherein the step of contacting is selected from the group consisting of topical application, systemic administration to the subject, injection,
10 electroporation, liposome application, viral-mediated contact, contacting the cell with the nucleic acid, and coculturing the cell with the nucleic acid.
18. The method of claim 17, wherein the administration of the contacting is selected from the group comprising topical
15 administration, adenovirus infection, viral-mediated infection, liposome-mediated transfer, topical application to the cells of the subject, microinjection, and catheterization.
19. A method of inducing a current in the heart in a subject which comprises contacting a cell of the heart of a subject with a
20 compound in a sufficient amount to induce a current in the cell of the heart of a subject, thereby inducing a current in the cell of the heart of the subject.
20. A method of increasing the heart rate in a subject which comprises contacting a cell of the heart of a subject with a
25 compound in an amount sufficient to decrease the time constant

-53-

of activation and deactivation of the cell of the heart,
thereby increasing the heart rate in the subject.

21. A method of inducing a current in a cell which comprises
contacting a cell with a compound in a sufficient amount to
5 induce a current in the cell, thereby inducing a current in the
cell.
22. A method of causing a contraction of a cell which comprises
contacting the cell with a compound in an amount sufficient to
induce a current required to cause a contraction of the cell,
10 thereby causing a contraction of the cell.
23. A method of shortening the time required to activate and
deactivate a cell which comprises contacting a cell with a
compound in a sufficient amount to decrease the time constant
of activation and deactivation of the cell, thereby shortening
15 the time required to activate and deactivate the cell.
24. A method of changing the membrane potential of a cell which
comprises contacting a cell with a compound in a sufficient
amount to change the membrane potential of the cell, thereby
changing the membrane potential of the cell.

FIGURE 1A 1/25




FIGURE 1B






FIGURE 1C



2/25



3/25




FIGURE 2B

4/25





FIGURE 3C I_{HCN2} in cultured adult





FIGURE 3D



6/25








FIGURE 4B










11/25



12/25

FIGURE 8A




FIGURE 8B




FIGURE 8C





FIGURE 9A






FIGURE 10A 16/25
-- HCN1




FIGURE 10B
-- HCN1+mink





FIGURE 10C
-- HCN1+MiRP1



-100nA
0.5sec

17/25

FIGURE 10D

-- HCN2






FIGURE 10E

-- HCN2 + minK



18/25

FIGURE 10F



19/25

FIGURE 10H




FIGURE 10G




FIGURE 11A




FIGURE 11B




FIGURE 11C





FIGURE 11D



22/25

FIGURE 11E






FIGURE 11F




23/25

FIGURE 12A



24/25

FIGURE 12B



25/25

FIGURE 13A




FIGURE 13B





FIGURE 13C



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 December 2002 (12.12.2002)

PCT

(10) International Publication Number
WO 02/098286 A3

- (51) International Patent Classification⁷: A01N 37/18, 43/04, A61K 31/70, 38/00 (74) Agent: WHITE, John, P.; Cooper & Dunahm LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).
- (21) International Application Number: PCT/US02/18249 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 6 June 2002 (06.06.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/875,388 6 June 2001 (06.06.2001) US (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicants: THE TRUSTEES OF COLUMBIA UNIVERSITY IN CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US). THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK [US/US]; Office of Technology Licensing and Industry Relations, N5002 Melville Library, Stony Brook, NY 11794-3369 (US). Published:
— with international search report
- (72) Inventors: ROSEN, Michael, R.; 25 East 86th Street, Apt. 14C, New York, NY 10028 (US). ROBINSON, Richard, B.; 67 Roosevelt Street, Cresskill, NJ 07626 (US). COHEN, Ira, S.; 23 Hawks Nest Road, Stony Brook, NY 11790 (US). YU, Han-Gang; 15 Hollow Road, Stony Brook, NY 11790 (US). (88) Date of publication of the international search report: 8 May 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/098286 A3

(54) Title: IMPLANTATION OF BIOLOGICAL PACEMAKER THAT IS MOLECULARLY DETERMINED

(57) Abstract: This invention provides for a method of inducing a current in the heart in a subject which comprises contacting a cell of the heart of a subject with a compound in a sufficient amount to induce a current in the cell of the heart of a subject. This invention also provides a method of treating a cardiac condition in a subject which comprises contacting a cell of the heart of the subject with a compound in an amount sufficient to increase the current expression of the cell, thereby treating the cardiac condition in the subject.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/18249

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01N 37/18, 43/04; A61K 31/70, 38/00

US CL : 514/2, 44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| T | US 2002/0155101 A1 (DONAHUE et al) 24 October 2002 (24.10.2002), see pages 15-16. | 1-6, 17-24 |
| X, P | NATTEL et al. Arrhythmogenic ionic remodeling-Adaptive responses with maladaptive consequences Trends in Cardiovascular Medicine, October 2001, Vol. 11, No. 7, pp. 295-301, see entire document. | 1-6, 17-24 |
| --- | | ----- |
| Y, P | | 8-16 |
| Y | US 6,231,518 B1 (GRABEK et al) 15 May 2001 (15.05.2001), see whole document. | 1-24 |
| X | WO 00/63434 A1 (UNIVERSITY OF UTAH RESEARCH FOUNDATION) 26 October 2000 (26.10.2000), see whole document, especially abstract, pages 43-48, 52-55. | 1-8, 17-24 |
| --- | | ----- |
| Y | | 9-16 |
| A | RUBANYI, GABOR The future of human gene therapy Molecular Aspects of Medicine. 2001, Vol. 22, pages 113-142. | 1-24 |

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "E" earlier application or patent published on or after the international filing date | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O" document referring to an oral disclosure, use, exhibition or other means | "&" document member of the same patent family |
| "P" document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

06 November 2002 (06.11.2002)

Date of mailing of the international search report

11 FEB 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Brian Whiteman

Telephone No. 703 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/18249

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☒

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-7, 17-24, drawn to a method of treating a cardiac condition in a subject which comprises contacting a cell of the heart of the subject with a compound in an amount sufficient to increase the current expression of the cell, thereby treating the cardiac condition in the subject. Species a), wherein the step of contacting the cell is systemic administration of the compound will be search with this Group. However, the other species in the group will be searched with the appropriate additional search fees.

Group II, claim(s) 8, drawn to a method of treating a cardiac condition in a subject which comprises contacting a cell of the heart of the subject with a compound in an amount sufficient to increase the current expression of the cell, thereby treating the cardiac condition in the subject, wherein the compound comprises a nucleic acid which encodes MiRP1.

Group III, claim(s) 9-12, drawn to a method of treating a cardiac condition in a subject which comprises contacting a cell of the heart of the subject with a compound in an amount sufficient to increase the current expression of the cell, thereby treating the cardiac condition in the subject, wherein the compound comprises a nucleic acid which encodes HCN channel.

Group IV, claim(s) 13-16, drawn to a method of treating a cardiac condition in a subject which comprises contacting a cell of the heart of the subject with a compound in an amount sufficient to increase the current expression of the cell, thereby treating the cardiac condition in the subject, wherein the compound comprises a nucleic acid which encodes HCN channel and a HCN channel.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

- a) systemic administration;
- b) topical application;
- c) injection electroporation;
- d) liposome application;
- e) viral mediated contact;
- f) contacting the cell with the nucleic acid; and
- g) co-culturing the cell with the nucleic acid.

The claims are deemed to correspond to the species listed above in the following manner:

- Claim 1 and claims dependent therefrom correspond to species a).
- Claim 1 and claims dependent therefrom correspond to species b).
- Claim 1 and claims dependent therefrom correspond to species c).
- Claim 1 and claims dependent therefrom correspond to species d).
- Claim 1 and claims dependent therefrom correspond to species e).
- Claim 1 and claims dependent therefrom correspond to species f).
- Claim 1 and claims dependent therefrom correspond to species g).

The following claim(s) are generic: claim 1.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

INTERNATIONAL SEARCH REPORT

PCT/US02/18249

The technical feature linking groups I-IV appears to be that they all relate to increases the current expression of a cell in the heart by administering a compound to the cell of the heart.

However, SCHMID et al. teaches orally administering a compound (oriprenaline) to increase the current expression of cardiac cells in a patient.

Therefore, the technical feature linking the inventions of Groups I-IV does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

The special technical feature of Group I is considered to be a method to increases the current expression of a cell in the heart by administering a compound to the cell of the heart.

The special technical feature of Group II is considered to be a gene therapy method to increases the current expression of a cell in the heart by administering a compound to the cell of the heart, wherein the compound is MiRP1.

The special technical feature of Group III is considered to be a gene therapy method to increases the current expression of a cell in the heart by administering a compound to the cell of the heart, wherein the compound is HCN channel.

The special technical feature of Group IV is considered to be a method to increases the current expression of a cell in the heart by administering a compound to the cell of the heart, wherein the compound comprises the nucleic acid which encode MiRP1 and HCN channel.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: (a) the routes of administration are different structurally and/or functionally with regard to their action.

Accordingly, Group I-IV and species a)-g) are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.

Continuation of B. FIELDS SEARCHED Item 3:

WEST 2.1, STN

search terms: therapy, treating, cardiac condition, HCN1, HCN2, HCN4, MiRP1, cardiac rhythm disorder, gene therapy, cell, contracting, stimulating, membrane potential, shortening time, heart rate, current

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.